Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR

Toumpanakis, Christos; Garland, J.; Marelli, Laura; Srirajaskanthan, Raj; Soh, Jade Xiao Jue; Davies, Philippa; Buscombe, J. R.; Caplin, Martyn

doi:10.1111/j.1365-2036.2009.04083.x

Cited by 57 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, prospective proof of this concept has never been produced, and there is an ongoing debate as to whether routine cholecystectomy is required or not [98,99] because the increased incidence of cholelithiasis does not consistently lead to increased clinical problems. It may therefore be individually decided by the operating surgeon depending on technical and clinical aspects (e.g.…”

Section: Concomitant Cholecystectomymentioning

confidence: 99%

ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

et al. 2012

View full text Add to dashboard Cite

Section: Concomitant Cholecystectomymentioning

confidence: 99%

ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

et al. 2012

View full text Add to dashboard Cite

“…Mean biochemical response rates (partial and complete response) for octreotide, octreotide long-acting release (LAR), and for long-acting lanreotide were 50.9% (range 28-77%), 51.4% (31.5-100%), and 39.0% (17.9-58%) respectively (Toumpanakis et al 2009, Modlin et al 2010c; Table 1). …”

Section: Symptomatic and Antiproliferative Effects Of Ssasmentioning

confidence: 99%

Neuroendocrine tumor disease: an evolving landscape

Frilling

Åkerström

Falconi

et al. 2012

Endocrine-Related Cancer

147

106

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a heterogenous group of tumors arising from a variety of neuroendocrine cell types. The incidence and prevalence of GEPNENs have markedly increased over the last three decades. Symptoms are often absent in early disease, or vague and nonspecific even in advanced disease. Delayed diagnosis is thus common. Chromogranin A is the most commonly used biomarker but has limitations as does the proliferative marker Ki-67%, which is often used for tumor grading and determination of therapy. The development of a multidimensional prognostic nomogram may be valuable in predicting tumor behavior and guiding therapy but requires validation. Identification of NENs that express somatostatin receptors (SSTR) allows for SSTR scintigraphy and positron emission tomography imaging using novel radiolabeled compounds. Complete surgical resection of limited disease or endoscopic ablation of small lesions localized in stomach or rectum can provide cure; however, the majority of GEP-NENs are metastatic (most frequently the liver and/or mesenteric lymph nodes) at diagnosis. Selected patients with metastatic disease may benefit from advanced surgical techniques including hepatic resection or liver transplantation. Somatostatin analogs are effective for symptomatic treatment and exhibit some degree of antiproliferative activity in small intestinal NENs. There is a place for streptozotocin, temozolomide, and capecitabine in the management of pancreatic NENs, while new agents targeting either mTOR (everolimus) or angiogenic (sunitinib) pathways have shown efficacy in these lesions.

show abstract

“…However, prospective proof of this concept has never been produced, and there is an ongoing debate as to whether routine cholecystectomy is required or not [100,101] because the increased incidence of cholelithiasis does not consistently lead to cholecystitis. It may therefore be individually decided by the surgeon, depending on technical and clinical aspects (e.g.…”

Section: Concomitant Cholecystectomymentioning

confidence: 99%

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

et al. 2016

Self Cite

View full text Add to dashboard Cite

Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR

Abstract: SUMMARY BackgroundOctreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long followup are lacking.

Cited by 57 publications

References 24 publications

ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

Neuroendocrine tumor disease: an evolving landscape

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

Contact Info

Product

Resources

About